Management of Rheumatoid Arthritis

Treatment Recommendations

The American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) support combination therapy for patients with inadequate response to a single conventional synthetic disease-modifying antirheumatic drug (csDMARD) 1, 2
For rheumatoid arthritis (RA) with low disease activity, hydroxychloroquine is conditionally recommended over other conventional csDMARDs 1
Methotrexate should be optimized to 15-25 mg/week before evaluating the full response to therapy, and the response to therapy should be evaluated at 4-6 weeks for initial improvement and at 3 months for determining efficacy 1, 2
If there is no significant improvement after 3 months with the combination of methotrexate and hydroxychloroquine, consider triple therapy (adding sulfasalazine) or evaluate the addition of a biologic or targeted synthetic DMARD 1, 2
For patients not adequately managed on methotrexate and hydroxychloroquine, the EULAR and ACR recommend adding a biologic DMARD (bDMARD) like adalimumab to the treatment regimen 3, 1
The ACR 2021 guideline conditionally recommends adding a bDMARD or a targeted synthetic DMARD (tsDMARD) over triple therapy for patients taking maximally tolerated doses of methotrexate who are not at target 1
Patients with high disease activity, early joint damage, positive RF/ACPA should receive more aggressive therapy, and patient-specific factors that might influence treatment choice, such as comorbidities, should be considered 3, 1

Hydroxychloroquine is typically used at 200-400 mg/day (typically 200 mg twice a day) 3, 1
Methotrexate should be maintained at 20-25 mg/week before adding a third agent 3, 1
Methotrexate dose should be optimized before evaluating the full response to therapy 1

Patients on hydroxychloroquine and warfarin should be carefully monitored for interactions 1
The combination of hydroxychloroquine and methotrexate may increase the incidence of adverse reactions, requiring monitoring 1
Baseline ophthalmologic evaluation and periodic follow-up are recommended to detect retinal toxicity 1
Patients should be monitored for potential cardiac effects (QT interval prolongation) 1
Before starting adalimumab, screen for tuberculosis and hepatitis B 4
Evaluate response to adalimumab at 3 months; if no improvement is seen, consider switching to a different class of biologic 3, 1

Don't wait too long to escalate therapy if the target is not achieved 3, 1
Cyclophosphamide is not recommended in current guidelines for RA management due to its toxicity profile and the availability of safer alternatives 1, 4
Azathioprine is not included in current treatment algorithms for RA and has been largely replaced by more effective and safer DMARDs 3, 5